HER2-targeting affibody bests FDG for imaging pulmonary metastases

My colleague’s (Gabriela Kramer-Marek) recent study,  named PET of HER2-Positive Pulmonary Metastases with 18F-ZHER2:342 Affibody in a Murine Model of Breast Cancer: Comparison with 18F-FD, was received with great attention by moculecular imaging researchers, and eventually hightlighted in MolecularImaging news. I congratulate Gabrieala for her great work that I have also been involved as a co-author and participated in the research for the image quantification/evaluation part.

Currently, I am working on the same data set that Gabriela provided in order to demonstrate my recent automated quantification tool and its use in small animal model for evaluation of disease progression longitudinally. Research report will be ready from this website once the peer review process has been finalized.

For the highlighted news of Gabriela’s approach:

http://www.molecularimaging.net/index.php?option=com_articles&view=article&id=34009&division=mii

For the research paper recently published is:

PET of HER2-Positive Pulmonary Metastases with 18F-ZHER2:342 Affibody in a Murine Model of Breast Cancer: Comparison with 18F-FDG.

Kramer-Marek, G.,  Bernardo, M.,  Kiesewetter, DO., Bagci, U.,  et al.

Journal of Nuclear Medicine, In press.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s